Table 2.

Treatment characteristics during TIL therapy and clinical outcome

PatientAge/sexPSLactate dehydrogenaseStageSite of biopsy*Evaluable metastasisIL-2 dosesResp.PFS (mo)OS (mo)
Responders (n = 10)
05-LA41/M0NormalM1aSCSC nodules10CR2020
19-NS66/M1NormalM1cPerito.Peritoneum3CR44
03-MG36/M0NormalM1cLNSoft tissue, lung, bone15PR921
06-TS60/M0NormalM1bLungLung5PR1818
09-SD45/M0NormalM1bLNLung7PR1313
13-BS61/M0NormalM1bLungLung9PR1010
14-SV71/M0AboveM1aSCSC, LN9PR39
16-SH41/M1NormalM1cSCLiver, adrenal, lung, LN8PR66
18-WR70/F0NormalM1aLNSC, LN8PR44
20-TY58/M0NormalM1aSCSC, LN7PR33
Median8.1 ± 3.2(7.3)(9.3)
Nonresponders (n = 10)
01-AY56/M0NormalM1cLungLung, SC, bone9SD1117
07-ZR22/M0NormalM1bLungLung7SD315
08-RM34/F0NormalM1cLiverLiver14SD56
12-VS41/F0NormalM1aSCSC, LN11SD1111
02-PE36/M0AboveM1cLNLN, adrenal, periton.9PD23
04-BA57/M0NormalM1cLungLN, lung, adrenal,13PD320
10-BE53/F0NormalM1cLNSC, LN, adrenal6PD15
11-KB57/M1AboveM1cLNLung, LN6PD15
15-SM52/M1AboveM1cLiverBone, liver10PD13
17-ZD68/F1AboveM1cPleuraLung, pleura, bone5PD12
Median9.0 ± 3.12.75.7
P = 0.53

Abbreviations: PS, performance status according to ECOG scale; Resp., best objective clinical response according to the RECIST criteria; PFS, PFS measured from day of TIL infusion; OS, OS measured from day of TIL infusion; LN, lymph node.

  • *Site of tumor sample for TIL harvest.

  • Ongoing.

  • Patients with HLA-A*0201.